Patents by Inventor Bishnu P. Joshi

Bishnu P. Joshi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glypican-3 peptide reagents and methods
    Patent number: 11248022
    Abstract: The present invention is directed to glypican-3-specific peptide reagents, methods for detecting hepatocellular carcinoma cells using the peptide reagents, and methods for targeting hepatocellular carcinoma cells using the peptide reagents.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: February 15, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Juan Zhou, Thomas D. Wang, Zhao Li, Bishnu P. Joshi
  • HER2 peptide regents and methods
    Patent number: 10858396
    Abstract: The present disclosure is directed to HER2-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or cancer cells using the peptide reagents.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 8, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Thomas D. Wang, Bishnu P. Joshi
  • Claudin-1 peptide reagents and methods
    Patent number: 10746738
    Abstract: The present invention is directed to claudin-1-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or cancer cells using the peptide reagents.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: August 18, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Thomas D. Wang, Emily Rabinsky, Bishnu P. Joshi
  • PEPTIDE REAGENTS AND METHODS FOR DETECTION AND TARGETING OF DYSPLASIA, EARLY CANCER AND CANCER
    Publication number: 20200102349
    Abstract: The present invention is directed to EGFR-specific and ErbB2-specific peptide reagents, methods for detecting pre-cancer, early cancer and/or cancer using the peptide reagents alone or in a multiplex format, and methods for targeting pre-cancer cells, early cancer cells and/or cancer cells using the peptide reagents.
    Type: Application
    Filed: December 9, 2019
    Publication date: April 2, 2020
    Inventors: Thomas D. Wang, Juan Zhou, Bishnu P. Joshi
  • Glypican-3 Peptide Reagents and Methods
    Publication number: 20200010508
    Abstract: The present invention is directed to glypican-3-specific peptide reagents, methods for detecting hepatocellular carcinoma cells using the peptide reagents, and methods for targeting hepatocellular carcinoma cells using the peptide reagents.
    Type: Application
    Filed: March 7, 2018
    Publication date: January 9, 2020
    Inventors: Juan Zhou, Thomas D. Wang, Zhao Li, Bishnu P. Joshi
  • Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer
    Patent number: 10500290
    Abstract: The present invention is directed to EGFR-specific peptide reagents, methods for detecting pre-cancer, early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancer cells, early cancer cells and/or cancer cells using the peptide reagents. In one aspect, the disclosure provides reagents consisting essentially of a peptide QRHKPRE (SEQ ID NO: 1), HAHRSWS (SEQ ID NO: 2), YLTMPTP (SEQ ID NO: 3), TYPISFM (SEQ ID NO: 4), KLPGWSG (SEQ ID NO: 5), IQSPHFF (SEQ ID NO: 6), YSIPKSS (SEQ ID NO: 7), SHRNRPRNTQPS (SEQ ID NO: 8), NRHKPREKTFTD (SEQ ID NO: 9).
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: December 10, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Thomas D. Wang, Juan Zhou, Bishnu P. Joshi
  • HER2 PEPTIDE REGENTS AND METHODS
    Publication number: 20180273584
    Abstract: The present disclosure is directed to HER2-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or cancer cells using the peptide reagents.
    Type: Application
    Filed: December 1, 2016
    Publication date: September 27, 2018
    Inventors: Thomas D. Wang, Bishnu P. Joshi
  • CLAUDIN-1 PEPTIDE REAGENTS AND METHODS
    Publication number: 20180052165
    Abstract: The present invention is directed to claudin-1-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or cancer cells using the peptide reagents.
    Type: Application
    Filed: February 25, 2016
    Publication date: February 22, 2018
    Inventors: Thomas D. WANG, Emily RABINSKY, Bishnu P. JOSHI
  • PEPTIDE REAGENTS AND METHODS FOR DETECTION AND TARGETING OF DYSPLASIA, EARLY CANCER AND CANCER
    Publication number: 20170246324
    Abstract: The present invention is directed to EGFR-specific peptide reagents, methods for detecting pre-cancer, early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancer cells, early cancer cells and/or cancer cells using the peptide reagents. In one aspect, the disclosure provides reagents consisting essentially of a peptide QRHKPRE (SEQ ID NO: 1), HAHRSWS (SEQ ID NO: 2), YLTMPTP (SEQ ID NO: 3), TYPISFM (SEQ ID NO: 4), KLPGWSG (SEQ ID NO: 5), IQSPHFF (SEQ ID NO: 6), YSIPKSS (SEQ ID NO: 7), SHRNRPRNTQPS (SEQ ID NO: 8), NRHKPREKTFTD (SEQ ID NO: 9).
    Type: Application
    Filed: August 21, 2015
    Publication date: August 31, 2017
    Inventors: Thomas D. Wang, Juan Zhou, Bishnu P. Joshi